Form D · Biotechnology
NeuImmune, Inc.
Sykesville, MD · CIK 0001860169
Offering snapshot reported Jul 15, 2021 · SEC filing
- Reported sold
- $20K Offering amount: $20K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $20K Reported outside-investor minimum
- First sale
- Jul 7, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 15, 2021 | Initial | $20,000 | No comparison | 1 | SEC filing |
| May 12, 2021 | Initial | $105,000 | No comparison | 6 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-406464
Source: Form D, filed Jul 15, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth C Carter | Director |
| Thomas R Fuerst | Director, Executive |
| Mark D Hankins | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1500 Fannie Dorsey Rd
Sykesville, MD, 21784
Sykesville, MD, 21784